251 related articles for article (PubMed ID: 31340155)
1. Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer.
Magen A; Das Sahu A; Lee JS; Sharmin M; Lugo A; Gutkind JS; Schäffer AA; Ruppin E; Hannenhalli S
Cell Rep; 2019 Jul; 28(4):938-948.e6. PubMed ID: 31340155
[TBL] [Abstract][Full Text] [Related]
2. Complex synthetic lethality in cancer.
Ryan CJ; Devakumar LPS; Pettitt SJ; Lord CJ
Nat Genet; 2023 Dec; 55(12):2039-2048. PubMed ID: 38036785
[TBL] [Abstract][Full Text] [Related]
3. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism.
Apaolaza I; San José-Eneriz E; Tobalina L; Miranda E; Garate L; Agirre X; Prósper F; Planes FJ
Nat Commun; 2017 Sep; 8(1):459. PubMed ID: 28878380
[TBL] [Abstract][Full Text] [Related]
4. SL
Liu Y; Wu M; Liu C; Li XL; Zheng J
IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(3):748-757. PubMed ID: 30969932
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethality on drug discovery: an update on cancer therapy.
Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
[TBL] [Abstract][Full Text] [Related]
6. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
7. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
Wang X; Zhang Y; Han ZG; He KY
Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
[TBL] [Abstract][Full Text] [Related]
8. Link synthetic lethality to drug sensitivity of cancer cells.
Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
[TBL] [Abstract][Full Text] [Related]
9. A systematic analysis of the landscape of synthetic lethality-driven precision oncology.
Schäffer AA; Chung Y; Kammula AV; Ruppin E; Lee JS
Med; 2024 Jan; 5(1):73-89.e9. PubMed ID: 38218178
[TBL] [Abstract][Full Text] [Related]
10. Identification of synthetic lethality based on a functional network by using machine learning algorithms.
Li J; Lu L; Zhang YH; Liu M; Chen L; Huang T; Cai YD
J Cell Biochem; 2019 Jan; 120(1):405-416. PubMed ID: 30125975
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.
Liu L; Chen X; Hu C; Zhang D; Shao Z; Jin Q; Yang J; Xie H; Liu B; Hu M; Ke K
Sci Rep; 2018 May; 8(1):8440. PubMed ID: 29855504
[TBL] [Abstract][Full Text] [Related]
12. Harnessing synthetic lethality to predict the response to cancer treatment.
Lee JS; Das A; Jerby-Arnon L; Arafeh R; Auslander N; Davidson M; McGarry L; James D; Amzallag A; Park SG; Cheng K; Robinson W; Atias D; Stossel C; Buzhor E; Stein G; Waterfall JJ; Meltzer PS; Golan T; Hannenhalli S; Gottlieb E; Benes CH; Samuels Y; Shanks E; Ruppin E
Nat Commun; 2018 Jun; 9(1):2546. PubMed ID: 29959327
[TBL] [Abstract][Full Text] [Related]
13. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
Ye H; Zhang X; Chen Y; Liu Q; Wei J
Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality-mediated precision oncology via the tumor transcriptome.
Lee JS; Nair NU; Dinstag G; Chapman L; Chung Y; Wang K; Sinha S; Cha H; Kim D; Schperberg AV; Srinivasan A; Lazar V; Rubin E; Hwang S; Berger R; Beker T; Ronai Z; Hannenhalli S; Gilbert MR; Kurzrock R; Lee SH; Aldape K; Ruppin E
Cell; 2021 Apr; 184(9):2487-2502.e13. PubMed ID: 33857424
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality: emerging targets and opportunities in melanoma.
Thompson N; Adams DJ; Ranzani M
Pigment Cell Melanoma Res; 2017 Mar; 30(2):183-193. PubMed ID: 28097822
[TBL] [Abstract][Full Text] [Related]
16. The tumor therapy landscape of synthetic lethality.
Zhang B; Tang C; Yao Y; Chen X; Zhou C; Wei Z; Xing F; Chen L; Cai X; Zhang Z; Sun S; Liu Q
Nat Commun; 2021 Feb; 12(1):1275. PubMed ID: 33627666
[TBL] [Abstract][Full Text] [Related]
17. Mapping the landscape of synthetic lethal interactions in liver cancer.
Yang C; Guo Y; Qian R; Huang Y; Zhang L; Wang J; Huang X; Liu Z; Qin W; Wang C; Chen H; Ma X; Zhang D
Theranostics; 2021; 11(18):9038-9053. PubMed ID: 34522226
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening.
Weng S; Ruan H
FEBS J; 2023 Mar; 290(6):1477-1480. PubMed ID: 36461713
[TBL] [Abstract][Full Text] [Related]
19. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
